External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients
Jazyk angličtina Země Austrálie Médium print-electronic
Typ dokumentu časopisecké články
PubMed
34553428
DOI
10.1111/iju.14701
Knihovny.cz E-zdroje
- Klíčová slova
- Epidemiology and End Results, Surveillance, cancer-specific mortality, external beam radiotherapy, localized prostate cancer, other-cause mortality, radical prostatectomy,
- MeSH
- černoši nebo Afroameričané MeSH
- lidé MeSH
- nádory prostaty * radioterapie chirurgie MeSH
- prostata MeSH
- prostatektomie * MeSH
- prostatický specifický antigen MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- prostatický specifický antigen MeSH
OBJECTIVES: To test the effect of race/ethnicity on cancer-specific mortality after radical prostatectomy or external beam radiotherapy in localized prostate cancer patients. METHODS: In the Surveillance, Epidemiology and End Results database 2004-2016, we identified intermediate-risk and high-risk white (n = 151 632), Asian (n = 11 189), Hispanic/Latino (n = 20 077) and African American (n = 32 550) localized prostate cancer patients, treated with external beam radiotherapy or radical prostatectomy. Race/ethnicity-stratified cancer-specific mortality analyses relied on competing risks regression, after propensity score matching for patient and cancer characteristics. RESULTS: Compared with white patients, Asian intermediate- and high-risk external beam radiotherapy patients showed lower cancer-specific mortality (hazard ratio 0.58 and 0.70, respectively, both P ≤ 0.02). Additionally, Asian high-risk radical prostatectomy patients also showed lower cancer-specific mortality than white patients (hazard ratio 0.72, P = 0.04), but not Asian intermediate-risk radical prostatectomy patients (P = 0.08). Conversely, compared with white patients, African American intermediate-risk radical prostatectomy patients showed higher cancer-specific mortality (hazard ratio 1.36, P = 0.01), but not African American high-risk radical prostatectomy or intermediate- and high-risk external beam radiotherapy patients (all P ≥ 0.2). Finally, compared with white people, no cancer-specific mortality differences were recorded for Hispanic/Latino patients after external beam radiotherapy or radical prostatectomy, in both risk levels (P ≥ 0.2). CONCLUSIONS: Relative to white patients, an important cancer-specific mortality advantage applies to intermediate-risk and high-risk Asian prostate cancer patients treated with external beam radiotherapy, and to high-risk Asian patients treated with radical prostatectomy. These observations should be considered in pretreatment risk stratification and decision-making.
Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic
Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria
Department of Urology Policlinico San Martino Hospital University of Genova Genoa Italy
Department of Urology University Hospital Frankfurt Frankfurt am Main Germany
Department of Urology University Hospital Hamburg Eppendorf Hamburg Germany
Department of Urology University of Texas Southwestern Dallas Texas USA
Department of Urology Weill Cornell Medical College New York City New York USA
Martini Klinik Prostate Cancer Center University Hospital Hamburg Eppendorf Hamburg Germany
Zobrazit více v PubMed
Mahal BA, Berman RA, Taplin M-E et al. Prostate cancer-specific mortality across Gleason Scores in Black vs Nonblack Men. JAMA 2018; 320: 2479.
Steele CB, Li J, Huang B et al. Prostate cancer survival in the United States by race and stage (2001-2009): findings from the CONCORD-2 study. Cancer 2017; 123: 5160-77.
Gray PJ, Lin CC, Cooperberg MR et al. Temporal trends and the impact of race, insurance, and socioeconomic status in the management of localized prostate cancer. Eur. Urol. 2017; 71: 729-37.
Man A, Pickles T, Chi KN. Asian race and impact on outcomes after radical radiotherapy for localized prostate cancer. J. Urol. 2003; 170: 901-4.
Chinea FM, Patel VN, Kwon D et al. Ethnic heterogeneity and prostate cancer mortality in Hispanic/Latino men: a population-based study. Oncotarget 2017; 8: 69709-21.
Chao GF, Krishna N, Aizer AA et al. Asian Americans and prostate cancer: a nationwide population-based analysis. Urol. Oncol. Semin. Orig. Investig. 2016; 34: 233.e7-233.e15.
Deuker M, Stolzenbach LF, Pecoraro A et al. PSA, stage, grade and prostate cancer specific mortality in Asian American patients relative to Caucasians according to the United States Census Bureau race definitions. World J. Urol. 2021; 39: 787-96.
Wang C, Kamrava M, King C et al. Racial disparity in prostate cancer-specific mortality for high-risk prostate cancer: a population-based study. Cureus 2017; 9: e961.
Dess RT, Hartman HE, Mahal BA et al. Association of black race with prostate cancer-specific and other-cause mortality. JAMA Oncol. 2019; 5: 975.
Fine JP, Gray RJ. A proportional Hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc. 1999; 94: 496-509.
Dignam JJ, Zhang Q, Kocherginsky M. The use and interpretation of competing risks regression models. Clin. Cancer Res. 2012; 18: 2301-8.
R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria. 2013. [Cited 30 Mar 2021.] Available from URL: http://www.r-project.org/
Lichtensztajn DY, Gomez SL, Sieh W et al. Prostate cancer risk profiles of Asian-American Men: disentangling the effects of immigration status and race/ethnicity. J. Urol. 2014; 191: 952-6.
Howlader N, Noone A, Krapcho M et al. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Bethesda, MD. 2018. Based on November 2018 SEER data submission, posted to the SEER web site, April 2019. [30 Mar 2021.] Available from URL: https://seer.cancer.gov
Nemirovsky A, Huang H, Al Kibria GM et al. Surgery associated with increased survival compared to radiation in clinically localized Gleason 9-10 prostate cancer: a SEER analysis. World J. Urol. 2021; 39: 415-23.
Pompe RS, Davis-Bondarenko H, Zaffuto E et al. Population-based validation of the 2014 ISUP Gleason Grade Groups in patients treated with radical prostatectomy, brachytherapy, external beam radiation, or no local treatment. Prostate 2017; 77: 686-93.
Cooperberg MR, Hinotsu S, Namiki M et al. Trans-Pacific variation in outcomes for men treated with primary androgen-deprivation therapy (ADT) for prostate cancer. BJU Int. 2016; 117: 102-9.
Fukagai T, Namiki TS, Carlile RG et al. Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men. BJU Int. 2006; 97: 1190-3.
